Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | HCC1806 is a human breast cancer cell line established from a primary stage IIB, grade 2 acantholytic squamous cell carcinoma of the breast in a 60-year-old female donor. The cells grow as an adherent epithelial-like monolayer and display a triple-negative, basal-like phenotype characterized by the absence of estrogen receptor, progesterone receptor, and HER2 amplification together with expression of EGFR and cytokeratin 5/6. HCC1806 carries a TP53 frameshift variant and homozygous FHIT exon 4 deletion, has a stable microsatellite phenotype, and forms tumors in xenograft models. These properties support mechanistic, multi-omic, genetic-screening, drug-response, and in vivo studies of basal-like triple-negative breast cancer. |
| Cell Type | Human breast carcinoma epithelial cell |
| Tissue of Origin | Breast |
| Disease | Breast acantholytic squamous cell carcinoma |
| Tumor Source | Primary breast tumor |
| Tumor Stage | Stage IIB |
| Histologic Grade | Grade 2 |
| Population Background | African American |
| Sex | Female |
| Age at Sampling | 60 years |
| Morphology | Epithelial-like, polygonal cells |
| Growth Mode | Adherent |
| Applications | 1. Triple-negative breast cancer biology 2. Basal-like breast cancer signaling and biomarker studies 3. EGFR and cytokeratin 5/6 research 4. Hormone-receptor-independent proliferation and survival assays 5. TP53- and FHIT-related tumor-suppressor studies 6. DNA-damage response and platinum sensitivity research 7. Cell viability, apoptosis, clonogenic, and drug-combination assays 8. Migration, invasion, and metastasis-related studies 9. CRISPR, RNA interference, and functional-genomics screens 10. Transcriptomic, epigenomic, proteomic, and pharmacogenomic profiling 11. Xenograft tumor growth and treatment-response studies 12. Comparative studies of breast-cancer subtype and ancestry-associated biology |
| Characteristics | |
| Molecular Subtype | Triple-negative, basal-like breast cancer model |
| Estrogen Receptor | Negative |
| Progesterone Receptor | Negative |
| HER2 Status | No HER2 amplification; classified as HER2 negative |
| Basal Markers | Positive for EGFR and cytokeratin 5/6 at the protein level; corresponding transcripts are detectable |
| TP53 Variant | Heterozygous TP53 c.766_767insAA, producing p.Thr256Lysfs*90 |
| FHIT Alteration | Homozygous deletion involving FHIT exon 4 |
| Microsatellite Status | Microsatellite stable |
| Chromosome Content | Aneuploid; a modal chromosome number of 75 is associated with the reference culture |
| Tumorigenicity | Forms tumors after subcutaneous implantation in immunodeficient mice and is suitable for xenograft growth and pharmacology studies |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Culture Conditions | 37°C in a humidified atmosphere containing 5% CO₂ |
| Culture Surface | Standard tissue-culture-treated vessels for routine monolayer propagation |
| Medium Renewal | Every 2–3 days, with frequency adjusted for cell density and experimental design |
| Dissociation Reagent | 0.25% trypsin with 0.53 mM EDTA |
| Split Ratio | 1:2 to 1:4 |
| Subculturing | 1. Passage healthy cultures before prolonged overconfluence. 2. Remove the spent medium and rinse the monolayer with calcium- and magnesium-free PBS. 3. Add enough 0.25% trypsin–0.53 mM EDTA to cover the cell layer. 4. Monitor cell rounding and detachment microscopically and avoid excessive exposure. 5. Add serum-containing complete medium to stop dissociation. 6. Gently disperse aggregates and collect the cell suspension. 7. Seed fresh vessels at a 1:2 to 1:4 ratio in complete RPMI-1640. 8. Return cultures to 37°C and 5% CO₂ and verify attachment and epithelial-like morphology. |
| Cryopreservation Medium | Complete growth medium supplemented with 5% DMSO |
| Cryopreservation | Harvest an actively growing culture, prepare a uniform suspension, and resuspend the cells in chilled cryopreservation medium. Dispense into labeled cryovials, cool at an approximately controlled rate, and transfer to liquid nitrogen for long-term storage. |
| Thawing | Rapidly thaw the vial at 37°C, disinfect the exterior, dilute the cell suspension with pre-warmed complete medium, remove residual cryoprotectant according to the local recovery workflow, and seed into a suitably sized vessel. Monitor attachment, morphology, and recovery before experimental use. |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR00639 | GFP Reporter Cell Line - HCC1806 | Inquiry |
| CSC-RR00768 | Luciferase Reporter Cell Line - HCC1806 | Inquiry |
| CSC-RO01593 | OVAL Stable Cell Line - HCC1806 | Inquiry |
| CSC-RO01846 | GFP/OVAL Stable Cell Line - HCC1806 | Inquiry |
| CSC-RO02099 | Luc/OVAL Stable Cell Line - HCC1806 | Inquiry |
| CSC-RO02352 | GFP/Luc/OVAL Stable Cell Line - HCC1806 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.